Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess pharmacokinetic and safety comparability of Bramitob®
when administered for inhalation by using PARI eFlow® rapid electronic nebulizer vs PARI LC®
PLUS nebulizer in Cystic Fibrosis Patients infected with Pseudomonas Aeruginosa